1.Gastrointestinal stromal tumors as an incidental finding in patients with a presumptive diagnosis of ovarian cancer.
Mario MUNOZ ; Pedro T RAMIREZ ; Carolina ECHEVERRI ; Luis Guillermo ALVAREZ ; Maria Alejandra PALOMINO ; Luis Rene PAREJA
Journal of Gynecologic Oncology 2012;23(1):48-52
OBJECTIVE: To report the clinical presentation and oncologic outcomes of a series of patients who presented with an abdominal or pelvic mass and were diagnosed with a gastrointestinal stromal tumor (GIST). METHODS: Data were obtained on all patients who presented with an abdominal or pelvic mass between September 2007 and June 2010 and who were ultimately diagnosed with a GIST. The patients' medical records were reviewed. A literature review was also conducted. RESULTS: Six patients were identified who met the inclusion criteria. All six patients had a tumor in the intestinal tract arising from the small bowel. The mean tumor size was 12 cm (range, 6 to 22 cm). A complete resection was achieved in five of the six patients. There were no intraoperative complications; one patient had a postoperative complication. Two patients were treated with imatinib after surgery. The mean follow-up time was 32 months (range, 0.3 to 40 months). At the last follow-up, five of the six patients were without any evidence of disease. One patient died of an unrelated hepatic encephalopathy. The incidence in our institution is 3%. CONCLUSION: GISTs are uncommon; however, they should be considered in the differential diagnosis of patients presenting with an abdominal or pelvic mass.
Benzamides
;
Diagnosis, Differential
;
Follow-Up Studies
;
Gastrointestinal Stromal Tumors
;
Hepatic Encephalopathy
;
Humans
;
Imatinib Mesylate
;
Incidence
;
Incidental Findings
;
Medical Records
;
Ovarian Neoplasms
;
Piperazines
;
Postoperative Complications
;
Pyrimidines